Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up

Annals of the Rheumatic Diseases

Volumn 71, Issue 9, 2012, Pages 1530-1533

  Van Den Broek, Marianne ^a   Dirven, L ^a   De Vries Bouwstra, J K ^a   Dehpoor, A J ^a   Goekoop Ruiterman, Y P M ^b   Gerards, A H ^c   Kerstens, P J S M ^d   Huizinga, T W J ^a   Lems, W F ^e   Allaart, C F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c Vlietland Hospital   (Netherlands)

^d Jan Van Breemen Research Institute/Reade   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HIGH RISK PATIENT; HUMAN; JOINT INJURY; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PHYSICAL DISABILITY; PREDICTION; PRIORITY JOURNAL; RADIATION PROTECTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED;

EID: 84864877081     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201212     Document Type: Article

References (7)

1. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1114-21.
3. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010;69:1333-7.
4. Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002;46:913-20. (Pubitemid 34303802)
5. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
6. Pope JE, Khanna D, Norrie D, et al. The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol 2009;36:254-9.
7. Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage. A definition based on patient perspective. J Rheumatol 2006;33:501-7. (Pubitemid 43334572)